DGAP-News: Dermapharm Holding SE to acquire Allergopharma

Dermapharm Holding SE to acquire Allergopharma

Grünwald, February 19, 2020 - Dermapharm, a leading manufacturer of patent-free branded pharmaceuticals for selected markets in Germany with a growing international presence, is acquiring Allergopharma, a company that specializes in therapeutics for desensitization of allergies, via Dermapharm Beteiligungs GmbH. To this end, Dermapharm signed a contract today to acquire Allergopharma GmbH & Co. KG, based in Reinbek near Hamburg, Germany, a subsidiary of Merck KGaA, Darmstadt, Germany. With the closing of the transaction Dermapharm Beteiligungs GmbH will acquire 100 percent of the shares in Allergopharma. The purchase agreement is still subject to approval by the relevant supervisory authority. The Management Board expects the transaction to be concluded by the end of the second quarter of 2020.

Allergopharma has over 50 years of experience in research and treatment of allergies. As a company that specializes in subcutaneous hyposensitization, Allergopharma is one of the leading providers in this field in Europe and offers a wide range of high-dosage hypoallergenic preparations, so-called allergoids. The portfolio also includes a large selection of allergens for diagnostics. Allergopharma's products are available in 18 countries. Sales abroad are handled by either the company's own teams or by external partners.

"By acquiring Allergopharma, we are expanding our expertise in the field of dermatology through an innovative portfolio for specific immunotherapy for allergies. Allergopharma is active in our core and future markets, making it an ideal acquisition as part of our growth strategy," commented Dr. Hans-Georg Feldmeier, Chairman of the Management Board of Dermapharm Holding SE, on the acquisition.

The parties have agreed not to disclose the purchase price.

Allergopharma is estimated to generate revenues of approximately EUR 90 million in 2020.

Dermapharm was advised by Ferber & Co. GmbH on this transaction.

Company profile:

Dermapharm - Pharmaceutical Excellence "Made in Germany"

Dermapharm is a leading manufacturer of patent-free branded pharmaceuticals for selected markets in Germany. Founded in 1991, the company is based in Grünwald near Munich and has its main manufacturing facility in Brehna near Leipzig. The company's integrated business model comprises in-house development, in-house production and distribution of pharmaceuticals and other healthcare products for specifically targeted markets by a medical and pharmaceutical sales force. Dermapharm has more than 900 marketing authorisations (Arzneimittelzulassungen) for approximately 250 active pharmaceutical ingredients, which are marketed as pharmaceuticals, dietary supplements or supplemental balanced diets. This assortment makes the company unique. In addition to Germany, the company's core markets also include Austria and Switzerland. The company plans to further expand its international presence. Dermapharm's business model also includes a parallel import business, which operates under the "axicorp" brand. Based on revenues, Dermapharm was among the top five parallel import companies in Germany in 2018. In the "Herbal Extracts" segment, Dermapharm has access to the growth market for herbal pharmaceuticals through the Spanish company Euromed S.A., one of the leading manufacturers of herbal extracts and natural active ingredients.

With a consistent R&D strategy and numerous successful product and company acquisitions over the past 25 years, Dermapharm has continuously optimised its business and provided external growth impulses in addition to organic growth. Dermapharm intends to continue on this profitable growth course in the future. The company is focusing on a three-pillar strategy: in-house development of new products, increase of its international footprint and further acquisitions.

Kontakt